Page 2 - லி கா ஷிங் நிறுவனம் ஆஃப் வைராலஜி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from லி கா ஷிங் நிறுவனம் ஆஃப் வைராலஜி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In லி கா ஷிங் நிறுவனம் ஆஃப் வைராலஜி Today - Breaking & Trending Today

New study may help explain low oxygen levels in COVID-19 patients

Date Time
New study may help explain low oxygen levels in COVID-19 patients
A new study published in the journal Stem Cell Reports by University of Alberta researchers is shedding light on why many COVID-19 patients, even those not in hospital, are suffering from hypoxia a potentially dangerous condition in which there is decreased oxygenation in the body’s tissues. The study also shows why the anti-inflammatory drug dexamethasone has been an effective treatment for those with the virus.
“Low blood-oxygen levels have been a significant problem in COVID-19 patients,” said study lead Shokrollah Elahi, associate professor in the Faculty of Medicine & Dentistry. “Because of that, we thought one potential mechanism might be that COVID-19 impacts red blood cell production.” ....

Wendy Sligl , Mohammed Osman , Shokrollah Elahi , Lorne Tyrrell , University Of Alberta , A Li Ka Shing Institute Of Virology , Li Ka Shing Institute Of Virology , Canadian Institutes Of Health Research , Stem Cell Reports , Fast Grants , Canadian Institutes , Health Research , Anti Inflammatory , Immune Response , Critically Ill , முகமது ஆஸ்மந் , லார்ன் டைரெல் , பல்கலைக்கழகம் ஆஃப் ஆல்பர்ட்டா , லி கா ஷிங் நிறுவனம் ஆஃப் வைராலஜி , கனடியன் நிறுவனங்கள் ஆஃப் ஆரோக்கியம் ஆராய்ச்சி , தண்டு செல் அறிக்கைகள் , வேகமாக மானியங்கள் , கனடியன் நிறுவனங்கள் , ஆரோக்கியம் ஆராய்ச்சி ,

Scientists identify receptor in cells that could be key to preventing cancer drug-induced hearing loss

Scientists identify receptor in cells that could be key to preventing cancer drug-induced hearing loss
University of Alberta scientists have identified a receptor in cells that could be key to preventing permanent hearing loss in childhood cancer survivors who are being treated with the drug cisplatin. The researchers believe by inhibiting the receptor, they may be able to eliminate toxic side-effects from the drug that cause the hearing loss.
Cisplatin is an incredibly effective chemotherapeutic when it comes to treating solid tumors in children, contributing to an 80 per cent overall survival rate over five years, according to U of A researcher Amit Bhavsar, an assistant professor in the Department of Medical Microbiology & Immunology. The problem has always been with the side-effects. Nearly 100 per cent of patients who receive higher doses of cisplatin show some degree of permanent hearing loss. The ability to prevent this side-effect would dramatically improve the qua ....

Frederick West , Ted Allison , Amit Bhavsar , Emily Henderson , Department Of Medical Microbiology Immunology , University Of Alberta , Department Of Biological Sciences , Mental Health Institute , Children Health Research Institute , Cancer Research Institute Of Northern Alberta , Li Ka Shing Institute Of Virology , Medical Microbiology , Biological Sciences , Mental Health , Cancer Research Institute , Northern Alberta , Health Research Institute , ஃப்ரெடரிக் மேற்கு , டெட் அல்லிசன் , அமித் பாவ்சர் , எமிலி ஹென்டர்சன் , துறை ஆஃப் மருத்துவ நுண்ணுயிரியல் நோயெதிர்ப்பு , பல்கலைக்கழகம் ஆஃப் ஆல்பர்ட்டா , துறை ஆஃப் உயிரியல் அறிவியல் , மன ஆரோக்கியம் நிறுவனம் , குழந்தைகள் ஆரோக்கியம் ஆராய்ச்சி நிறுவனம் ,

Researchers pinpoint possible way to prevent permanent hearing loss caused by cancer drug

E-Mail
IMAGE: University of Alberta researcher Amit Bhavsar is leading a team that has identified a receptor in cells that could be key to preventing permanent hearing loss in childhood cancer survivors.
view more
Credit: William Au
University of Alberta scientists have identified a receptor in cells that could be key to preventing permanent hearing loss in childhood cancer survivors who are being treated with the drug cisplatin. The researchers believe by inhibiting the receptor, they may be able to eliminate toxic side-effects from the drug that cause the hearing loss.
Cisplatin is an incredibly effective chemotherapeutic when it comes to treating solid tumours in children, contributing to an 80 per cent overall survival rate over five years, according to U of A researcher Amit Bhavsar, an assistant professor in the Department of Medical Microbiology & Immunology. The problem has always been with the side-effects. Nearly 100 per cent of patients w ....

Frederick West , Ted Allison , Amit Bhavsar , University Of Alberta , Department Of Biological Sciences , Mental Health Institute , Children Health Research Institute , Li Ka Shing Institute Of Virology , Canadian Institutes Of Health Research , Department Of Medical Microbiology Immunology , Stollery Children Hospital Foundation , Cancer Research Institute Of Northern Alberta , Medical Microbiology , Biological Sciences , Mental Health , Cancer Research Institute , Northern Alberta , Health Research Institute , Canadian Institutes , Health Research , Stollery Children , Hospital Foundation , ஃப்ரெடரிக் மேற்கு , டெட் அல்லிசன் , அமித் பாவ்சர் , பல்கலைக்கழகம் ஆஃப் ஆல்பர்ட்டா ,

Researchers Find Marker that Could Predict Response to Cancer – The News Chronicle

Micorscope is used by researcher who use her hands holding and adjusting while science research in laboratory
Researchers at University of Alberta have uncovered a link between the expression of the protein galectin-9 (gal-9) and whether a cancer patient will benefit from immunotherapy.
The discovery could help inform physicians about which patients will likely respond to immunotherapy, and lead to better treatment options.
Shokrollah Elahi, a member of the Cancer Research Institute of Northern Alberta (CRINA), collaborated with oncology professor John Walker on Phase 2 clinical trial that examined 40 patients with virus-associated solid tumours (VASTs) who were put on immunotherapy.
They found there was a direct link between patients with high levels of gal-9 and those who had a poor prognosis and did not respond to immunotherapy. Further, patients with lower levels of gal-9 responded better to treatment. ....

Shokrollah Elahi , Alberta Cancer Foundation , Cancer Research Institute Of Northern Alberta , Children Health Research Institute , Canadian Institute Of Health Research , Researchers At University Of Alberta , Li Ka Shing Institute Of Virology , Cancer Research Institute , Northern Alberta , John Walker , Health Research Institute , Canadian Institute , Health Research , ஆல்பர்ட்டா புற்றுநோய் அடித்தளம் , புற்றுநோய் ஆராய்ச்சி நிறுவனம் ஆஃப் வடக்கு ஆல்பர்ட்டா , குழந்தைகள் ஆரோக்கியம் ஆராய்ச்சி நிறுவனம் , கனடியன் நிறுவனம் ஆஃப் ஆரோக்கியம் ஆராய்ச்சி , லி கா ஷிங் நிறுவனம் ஆஃப் வைராலஜி , புற்றுநோய் ஆராய்ச்சி நிறுவனம் , வடக்கு ஆல்பர்ட்டா , ஜான் வாக்கர் , ஆரோக்கியம் ஆராய்ச்சி நிறுவனம் , கனடியன் நிறுவனம் , ஆரோக்கியம் ஆராய்ச்சி ,

University of Alberta lab reveals how a much-needed oral antiviral drug confuses replication machinery of SARS-CoV-2

Date Time
Share
University of Alberta lab reveals how a much-needed oral antiviral drug confuses replication machinery of SARS-CoV-2
A University of Alberta virology lab has uncovered how an oral antiviral drug works to attack the SARS-CoV-2 virus, in findings published May 10 in the Journal of Biological Chemistry.
The researchers demonstrated the underlying mechanism of action by which the antiviral drug molnupiravir changes the viral genome, a process known as excessive mutagenesis or “error catastrophe.”
“The polymerase, or replication engine of the virus, mistakes molnupiravir molecules for the natural building blocks required for viral genome replication and mixes them in,” explained Matthias Götte, professor and chair of the Department of Medical Microbiology & Immunology in the Faculty of Medicine & Dentistry and member of the Li Ka Shing Institute of Virology. “It causes the polymerase to make sloppy copies nonsense genomes that are usele ....

United States , Ridgeback Biotherapeutics , Raymond Schinazi , Egor Tchesnokov , Calvin Gordon , University Of Alberta , A University Of Alberta , World Health Organization , Alberta Ministry Of Jobs , Li Ka Shing Institute Of Virology , Canadian Institutes Of Health Research , Department Of Medical Microbiology Immunology , Emory School Of Medicine , Emory University In Atlanta , Us National Institutes Of Health Centers , Medical Microbiology , Emory University , Canadian Institutes , Health Research , Alberta Ministry , Health Centers , Emory School , ஒன்றுபட்டது மாநிலங்களில் , கால்வின் கோர்டந் , பல்கலைக்கழகம் ஆஃப் ஆல்பர்ட்டா , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் ,